Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2
Masato Furuhashi(Harvard University), Gökhan S. Hotamışlıgil(Harvard University), Jeffrey A. Robl(Bristol-Myers Squibb (Germany)), Eric Vaillancourt(Harvard University), Gürol Tuncman(Harvard University), Liza Makowski(University of Tennessee Health Science Center), Vladimir R. Babaev(Vanderbilt University Medical Center), Richard Sulsky(Bristol-Myers Squibb (Germany)), Sergio Fazio(Alzheimer's Association), MacRae F. Linton(Vanderbilt University), Rex A. Parker(Bristol-Myers Squibb (United States)), Gen‐ichi Atsumi(Teikyo University), Keita Kono(Harvard University), Cem Z. Görgün(Harvard University)
Cited by 732
Related Papers
Inflammation, stress, and diabetes
|Journal of Clinical Investigation|2005|3.9k
Current Perspectives on Statins
|Circulation|2000|1.2k
Genetic deficiency and pharmacological stabilization of mast cells reduce diet-induced obesity and diabetes in mice
|Nature Medicine|2009|775
Lack of macrophage fatty-acid–binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis
|Nature Medicine|2001|692
Neuronal PTP1B regulates body weight, adiposity and leptin action
|Nature Medicine|2006|626